PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro

Dalia Martinez-Marin\textsuperscript{1,*}, Courtney Jarvis\textsuperscript{1,2,*}, Thomas Nelius\textsuperscript{1}, Werner de Riese\textsuperscript{1}, Olga V. Volpert\textsuperscript{3,#}, Stéphanie Filleur\textsuperscript{1,2,*}

\textsuperscript{1} Department of Urology, Texas Tech University-Health Sciences Center, Lubbock, Texas, United States of America, \textsuperscript{2} Department of Immunology and Molecular Microbiology, Texas Tech University-Health Sciences Center, Lubbock, Texas, United States of America, \textsuperscript{3} Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America

\# These authors contributed equally to this work.
\* Current address: Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
\* Stephanie.filleur@ttuhsc.edu

Abstract

Background

Although inflammation and prostate cancer (PCa) have been linked, the molecular interactions between macrophages and PCa cells are poorly explored. Pigment Epithelium-Derived Factor (PEDF) is an anti-angiogenic and anti-tumor factor. We previously showed that PEDF induces macrophages recruitment \textit{in vitro}, correlates with macrophages density in human prostate, and stimulates macrophages polarization towards the classically activated pathway. Here, we demonstrate that PEDF modulates the interaction between macrophages and PCa cells through a bidirectional signalling leading to tumor cell apoptosis and phagocytosis.

Methods

RAW 264.7 and THP-1 cells, and BMDMs were grown \textit{in vitro} as mono- or co-cultures with PC3 or CL1 tumor cells. The effects of PEDF and its derived P18 peptide were measured on macrophages differentiation, migration, and superoxide production, and tumor cell apoptosis and phagocytosis. PEDF receptors (ATP5B, PNPLA2, and LRP6) and CD47 mRNA and protein expression were quantified in macrophages and tumor cells by quantitative RT-PCR, western blot, immunofluorescence and flow cytometry.

Results

We found that PEDF induced the migration of macrophages towards tumor 3D spheroids and 2D cultures. In co-culture, PEDF increased PCa cells phagocytosis through an indirect apoptosis-dependent mechanism. Moreover, PEDF stimulated the production of superoxide by macrophages. Conditioned media from macrophages exposed to PEDF induced tumor cells apoptosis in contrast to control conditioned media suggesting that ROS may be
involved in tumor cells apoptosis. ATP5B and PNPLA2 PEDF receptors on macrophages and CD47 on tumor cells were respectively up- and down-regulated by PEDF. As PEDF, blocking CD47 induced phagocytosis. Inhibiting ATP5B reduced phagocytosis. Inversely, PNPLA2 inhibition blocks differentiation but maintains phagocytosis. CD47-induced phagocytosis was partially reverted by ATP5B inhibition suggesting a complementary action. Similar effects were observed with P18 PEDF-derived peptide.

**Conclusions**

These data established that modulating the molecular interactions between macrophages and PCa cells using PEDF may be a promising strategy for PCa treatment.

**Introduction**

The tumor microenvironment is constituted by various cell types including inflammatory cells [1]. Among inflammatory cells, tumor-associated macrophages (TAMs) represent the predominant cell population. TAMs are characterized by a phenotypic plasticity and polarize into two main subsets, M₁ (classically activated) or M₂ (alternatively activated) macrophages depending on the surrounding environment. Accumulation of M₂-type macrophages (Arg1+/IL12<sub>Low</sub>/IL10<sub>High</sub>) or the enrichment of TAM-associated gene signatures have been correlated with poor prognosis and disease outcome in several types of cancer [2–5]. TAMs play a role in matrix remodeling and angiogenesis in multiple human tumors [6–8]. TAMs secreted a wide range of pro-angiogenic mediators such as bFGF, thymidine phosphorylase, uPA, and adrenomedullin [1]. At hypoxic tumor sites, HIF-1α up-regulates VEGF-A expression in TAMs [9] and, MMP-1, -7 and -9 proteolytic enzymes [10–12]. CXCL12 expression in gastric cancer and activation of the β-catenin pathway correlate with increased microvascular density and invasiveness [13, 14]. In the same cancer type, IL-25 was positively associated with histological grade and was found to be an independent predictor of favorable survival [15]. CCL18 and CXCL8 produced by TAMs were positively linked with microvessel density and metastatic potential in breast and thyroid papillary cancer [16, 17]. TAMs also produce immunosuppressive factors such as PGE<sub>2</sub>, IDO, TGFβ and IL10 to recruit immunosuppressive T regulatory cells [8]. TAMs serve as the main players for impeding the therapeutic activities of radiotherapy, chemotherapy, anti-hormonal, immunotherapy, and molecular targeting therapies [18–23] therefore emphasizing macrophages as an important therapeutic target.

In contrast to M₂, M₁ macrophages (iNOS+/IL12<sub>High</sub>/IL10<sub>Low</sub>) have tumoricidal activity, produce high amount of inflammatory cytokines, ROS and present a strong innate and adaptive immune activity. In non-small cell lung cancer, the M₁, but not M₂, macrophage density in tumor islets positively correlated with survival time [24]. Infiltration of diametrically polarized macrophages (M₁/M₂) predicts overall survival of patients with gastric and ovarian cancer, and renal cell carcinoma [25–27]. In PCa, Lissbrant et al. linked the volume density of TAMs to a shorter survival time, while Shimura et al. reported high TAMs number to be an independent predictor of disease-free survival after surgery for this disease [28, 29]. In agreement with Lissbrant’ study, the inhibition of macrophages function or pro-inflammatory pathways in PCa cells delayed tumor growth in experimental in vivo models [30]. Several TAM-targeting cancer therapy strategies are currently been tested: i) inhibiting macrophage recruitment; ii) suppressing TAM survival; iii) enhancing M₁ tumoricidal activity of TAMs; and iv) blocking M₂ tumor-promoting activity of TAMs [7]. While suppressing TAM recruitment/
survival are attractive options [8], reprogramming toward an anti-tumor M₁ phenotype appears to be a better target for clinical testing.

Pigment Epithelium-Derived Factor (PEDF) is a secreted angio-inhibitor with anti-tumor activities and suggested immune-modulatory properties [31–33]. We have previously demonstrated that PEDF induces the migration of macrophages and their polarization towards the classically activated pathway [34]. In human prostate, we showed that PEDF expression correlates with macrophage density. Accordingly, PEDF expression increased macrophages density in the orthotopic MatLyLu rat PCa model [35]. Still the precise role of PEDF in modulating the molecular interactions between macrophages and PCa cells remain uncharacterized. Herein, we report that PEDF directs macrophages towards tumor spheroids. Using co-culture, we showed that PEDF also stimulates the polarization of macrophages leading to tumor cell phagocytosis. PEDF-induced phagocytosis was apoptosis-dependent, but was not caused by a direct tumoricidal effect of PEDF on tumor cells. In contrast, PEDF stimulated the production of superoxide radicals by the macrophages. Furthermore, conditioned media from PEDF-treated macrophages induced apoptosis in tumor cells when compared to control media. ATP5B and PNPLA2, two known receptors for PEDF, were highly expressed in primary macrophages and cell line, and were up-regulated by PEDF. Inversely, the “don’t eat me” CD47 signal, expressed on the tumor cell surface was repressed by PEDF. Blocking CD47 induced phagocytosis. Inversely, inhibiting ATP5B significantly reduced phagocytosis. In contrast, inhibition of PNPLA2 blocks differentiation but maintains phagocytosis. PEDF’s inflammatory properties were reproduced by the PEDF-derived and anti-tumor P18 peptide. Thus, our data illustrated a novel PEDF-mediated signaling involving PNPLA2 up-regulation on macrophages to induce M₁ polarization and, CD47 down-regulation on tumor cells which in collaboration with ATP5B elevation on macrophages leads to phagocytosis.

**Materials and methods**

**Cells & reagents**

The androgen-refractory PCa (CRPC) PC3, androgen-sensitive Tramp-C1, RAW 264.7 and THP-1 cells were from the ATCC (Manasses, VA). CRPC CL1 cell line was a gift from Dr. Bell-degrun (Un. of California, LA). CL1 cells were derived as an androgen-independent variant from the human androgen-sensitive LNCaP cells as described in [36]. PC3 were grown in RPMI1640 with 10% fetal bovine serum (FBS). PC3-DsRed Express (designated as PC3-Ctrl), PC3-DsRed Express-PEDF (designated as PC3-PEDF), CL1-DsRed express (CL1-Ctrl) and CL1-DsRed express-PEDF cells (CL1-PEDF, passages 4–12) were established and grown as we described in [36, 37]. Tramp-C1 cells were grown in DMEM with 5% nu serum/5% FBS, 0.005 mg/ml Bovine insulin and 10 nM DHT. RAW 264.7 and THP-1 cells were grown between passages 1–12 to block gene loss and impaired macrophage immune function using RPMI1640 with 10% FBS. For macrophages differentiation/activation, monocytes/macrophages were treated for 48 hrs with 50 nM PMA/phorbol 12-myristate 13-acetate (Sigma Aldrich, St. Louis, MO) followed by PEDF treatment (BioProducts, Middletown, MD) in serum-free medium. P18 was a gift from Dr. Volpert [38]. ZVAD was from BD Pharmingen (San Diego, CA). To inhibit PNPLA2, macrophages were treated for 30’ with 5 μM of the irreversible antagonist (S)-BEL (Cayman Chemical; Ann Arbor, MI) before PCa co-culture or with 40 μM Atglistatin (Sigma-Aldrich, Milwaukee, WI) at the time of the co-culture. For ATP5B inhibition, 10 nM angiotatin (BioVision; Milpitas, CA) was added to the co-culture. CD47 Ab was from BD Biosciences (B6H12, San Jose, CA).
3D tumor spheroid assays

Tumor spheroid assays were performed using the 3-D Culture Matrix™ Basement Membrane Extract Reduced Growth Factor (Trevengen, Gaithersburg, MD). 1x10^4 CL1-Ctrl (Red) PCa cells/ml were diluted in 24ml of Assay Medium (98ml of growth media plus 2ml of 3-D Culture Matrix RGF BME). 500μl of PCa cell suspension were then added to each well of a 48 well plate pre-coated with 3-D Culture Matrix RGF BME. Cell growth and structure formation were observed every other day using the Nikon T1-E microscope. The medium was changed every three days. Once spheroids reached a diameter of ~600μm, 4x10^5 of green-fluorescent macrophages (CellTracker Green CMFDA, Invitrogen) with or without PEDF or P18 peptide were added to each well. After 24 hours, macrophages migrations towards the tumor spheroids was visualized using the Nikon T1-E 200 microscope (63X, Z-stack). Before imaging of the tumor spheroids within the 48-well plate, wells were filled with Cell Superfusion Buffer (CSB: 0.35mM Na2HPO4, 110mM NaCl, 0.44mM KH2PO4, 5.4mM KCl, 1mM MgSO4, 1.3mM CaCl3, 25mM HEPES, pH 7.4). After imaging, the Z-stack was merged, and the distance between the macrophages (Green) and the tumor spheroids (Red) was calculated using the two point analysis function (NIS-Elements AR 4.00.03, Carl Zeiss).

Phagocytosis in vitro assay

RAW 264.7 and THP-1 macrophages were seeded (3.5–7.5x10^5) on PCa CL1-Ctrl or PC3-Ctrl cells (2.5x10^4; Red) in 6-well plates containing 25 mm round sterile cover glass in serum-free medium supplemented with 50 nM PMA ± 10 nM PEDF or P18 peptide [39]. Cells (100/condition treatment) were live imaged at 48 hours using the Nikon T1-E 200 microscope (63X, Z-stack). Before imaging, cover glass was placed in Attoflour Cell Chamber (Life Techn.) and filled with 1 ml of CSB. Region of interest (ROI) were selected, and the intensity surface plot function (NIS-Elements AR 4.00.03; S1 Fig) was used to measure the signal intensity of each ROI. ROI mean intensity was calculated from >30 representative ROI (S1 Fig). To perform spectral imaging microscopy and obtain a spectral output, a Spectra-Pro-300i spectrograph (Acton Research Instruments, Acton, MA) was directly coupled to the side port of an Olympus IX70 inverted microscope through a C-mount adaptor (IX-TVAD). We also used a high dynamic range from transfer back illuminated cryogenically cooled Charged Coupled Device (CCD) camera (Spec10:400 B, LN; 16bit, Princeton Instruments, Trenton, NJ). The CCD temperature was maintained at -100˚C for all the experiments. The slit spectrograph was set at 200 μm throughout the experiments except for the zero order spectra, which was set to 3 mm. The length of the cell area was delimited by the 0.5 μm slit width and was divided into 16 discrete cellular regions of interest (S2 Fig, ROI were chosen in different areas around the cytoplasm of the cancer cells, the vacuoles of the macrophages that displayed red fluorescence, and various regions of the background to establish a baseline), allowing for images with high spectral, temporal, and spatial resolution. As negative controls, ROIs were selected in non-fluorescent cytoplasmic and extra-cellular regions of RAW 264.7 cells grown as mono- or co-culture. The optical filters used for the excitation of dsRed-Express were 545 nm narrow bandpass excitation filter, 570 nm long bandpass dichroic mirror. A 60x objective (N.A 1.4; oil) was used. The fluorescence data was converted to ASCII format, prior to analysis with SigmaPlot (version 8.0).

Cell cycle analysis

CL1 PCa cells were initially seeded in a 6-well dish at 1 X 10^5 cells/well and allowed to grow for 48 hours before being treated with or without 10 nM PEDF. Cells were harvested with trypsin and fixed overnight in 70% ethanol at 4˚C. Cells were then stained with a solution of 69 μM
propidium iodide in 38 mM Sodium Citrate (pH 7.4), and incubated for 45 minutes at 37˚C. For the cell cycle analysis, cells were initially gated for singlet cells before recording 10,000 events using a BD FACS Aria (BD Biosciences). Within each experiment, each sample was tested in triplicate; each experiment was repeated at least three times.

TUNEL labeling
RAW 264.7 macrophages were incubated in serum-free medium with or without 10 nM PEDF. After 48 hours, cell conditioned Media (CM and CM-PEDF) were collected and cleared from cell debris by centrifugation. The supernatant was then added to 70% confluent CL1 cells. After 24 hours, tumor cells were fixed and stained with ApopTag kit (Millipore, Norcross, GA). Apoptosis was measured in >200 cells per treatment using the Zeiss Axiovert microscope as we previously described in [33]. Nuclei were counter-stained with 4’, 6-diamino-phenol-indole (DAPI).

Cellular ROS/superoxide radicals
Free radicals and other reactive species were detected using the Cellular ROS/Superoxide Detection Assay Kit (Abcam) as recommended by the manufacturer. 1x10^4 RAW 264.7 macrophages per 96-well were seeded and treated as for the phagocytosis assay. After 48 hours, the culture medium was removed. The cells were then incubated with the ROS/Superoxide Detection Mix for 30 min at 37˚C. After washing, Oxidative Stress (ROS; Green) and O2^- (Red) -positive cells were counted and reported to the total amount of cell using the Zeiss Axiovert microscope. A minimum of 200 cells were counted per treatment condition and each treatment was tested in quadruplicate within a single experiment.

Bone Marrow-Derived Macrophages (BMDMs) collection
BMDMs were collected from C57BL6 tumor-free and tumor-bearing mice. For the tumor-bearing mice, 5x10^6 Tramp-C1 cells were s.c. injected into the hindquarters of male C57BL6 mice (6–8 weeks, Charles River). After 3 weeks, BMDMs were collected from the mice femur and tibia [40]. Cells were seeded at low density in RPMI1640 plus 10% FBS and 10% L929 cell condition media. Experiments were conducted after a minimum of ten days. Purity (> 95%) was verified by flow cytometry on a BD FACS Aria (BD Biosciences; 10,000 events counted) using F4/80 and Mac1 macrophages-specific markers (BD Pharmingen). This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by Texas Tech University Health Sciences Center Institutional Animal Care and Use Committee (A3056-1).

Immunofluorescence
60% confluent RAW 264.6 macrophages and BMDMs were fixed with 4% paraformaldehyde, quenched with 50mM PBS-NH4Cl, and blocked with 1% PBS-BSA. Cells were then incubated with α-ATP5B (Santa Cruz Biotechn., Dallas, TX) or α-PNPLA2 (R&D Systems, Minneapolis, MN) and incubated with fluorescent tag secondary antibody. Cells were mounted to cover slide with ProLong® Gold antifade (LifeTechnologies, Grand Island, NY) reagent containing DAPI nuclei staining. ~200 cells/condition were imaged using the Zeiss AxioVert 200 microscope. CD47 and LAMP1 were visualized on living cells. CD47-blocking antibody (100 ng/μl, B6H12) was added to the tumor cells 30 minutes before co-culturing with macrophages. α-LAMP1 (100 ng/μl, 1D4B, BD Transduction Lab) was added at the time of the co-culture.
RNA extraction and qRT-PCR

RNAs were extracted (RNeasy kit, Qiagen, Valencia, CA) and converted into cDNA (Verso cDNA kit, Thermo Scientific, Pittsburgh, PA). PEDF receptors cDNA: ATP5B (5′-GTTCATCCTGGCCAGAGAC-3′/5′-CGATGACTGCCACGATT-3′), PNPLA2 (5′-TCCAAGGGGTGCCTAT-3′/5′-GCTCATAAAGTGGCAAGTTGTC-3′), LRP6 (5′-TCTCCGCGAATTGAAAG-3′/5′-GAGTCTTCTAGCATGATCCTTG-3′; Thermo Scientific), CD47 (NM_001777.3), and SIRPα (NM_007547.4, Qiagen) were amplified: 1× heating for 10 min at 95˚C; 40× denaturing for 15 s at 95˚C, followed by annealing/extension 15 sec at 60˚C/60 s extension for 20 sec at 60˚C. As reference, S15 (5′-CAACGGCAAGACCTTCAAC-3′/5′-GGCTTTAGGATGGAGAAC-3′) was amplified; C_T values were determined by automated threshold analysis with MyIQ version 1.0 software. Fold change for each gene was calculated using the ΔΔC_T method. Each sample was tested in triplicate. For the CD47 and SIRPα qRT-PCR, RNAs were extracted directly from the PCa-macrophages co-culture, based on the fact that CD47 and SIRPα are exclusively expressed by PCa and macrophage cells, respectively [41].

Western blot

Whole cell lysates (50 mM Tris, 5 mM EDTA, 150 mM NaCl, 0.5% NP-40, 1 mM PMSF, pH 8.0) were separated by 4–15% SDS-PAGE and transferred onto PVDF membrane. After blocking (10 ml Tris-base, 100 ml NaCl, 0.1% Tween 20 (pH 7.5) with 5% nonfat dry milk), membranes were exposed to α-ATP5B or PNPLA2, and horseradish peroxidase-conjugated secondary Ab and; developed (ECL kit, Amersham, Pittsburgh, PA). Protein loading was controlled using β-actin.

Plasma membrane CD47 staining

CL1-Ctrl and CL1-PEDF PCa cells (1×10^6) were incubated with α-CD47/isotype FITC (B6H12, 200 ng/μl), and analyzed using the INSPIRE ImageStreamX MKII Amnis (3×10^4 events). Plasma membrane CD47 was quantified using the masking function of the IDEAS Analysis v6.1 software.

Statistical analyses

Data are expressed as mean ± standard deviation of two to three independent experiments, each done at least in triplicate. Statistical evaluation of the data was done using Student’s T-test or One-Way analysis of variance (ANOVA) where appropriate (SPSS 23 software for Windows). P values < 0.05 (*) were considered statistically significant.

Results

PEDF stimulates the migration towards tumor spheroids and the phagocytic activity of macrophages in vitro

We have previously demonstrated that PEDF induces the migration and polarization of human and mouse macrophages towards a M1 phenotype in vitro. We have also shown that PEDF expression positively correlates with macrophage density in the human prostate gland [34]. To link PEDF inflammatory activity to PCa we now investigate the effect of PEDF on the migration of macrophages towards prostate tumor spheroids and the phagocytosis of PCa cells in vitro. Using the highly reproducible CL1 tumor spheroids model, we demonstrated that macrophages (Green) were located in the periphery of the control spheroids (Red). In contrast, in the presence of PEDF, macrophages were found on the surface or infiltrating the spheroids (Fig 1A; arrows). Using the two point analysis function of the NIS-Elements AR 4.00.03
software (Carl Zeiss), we measured the distance between the spheroid and macrophages, and confirmed that PEDF directs the macrophages towards the spheroid (Fig 1B). To note, PEDF had no apparent effect on the tumor cell morphology within the spheroids. Similarly to the tumor spheroid, in the inverted Boyden chamber assay, the migration of RAW 264.7 macrophages was specifically induced by PEDF endogenously expressed by PC3 and CL1 PCa cell lines (S3 Fig).

To evaluate PCa cells phagocytosis, we performed cytotoxicity assays by co-culturing mouse RAW 264.7 macrophages and target human PC3 and CL1 PCa cells under PEDF/control treatments as described in [42]. As expected, PEDF induced the differentiation of macrophages when compared to untreated control (Fig 2A; thin arrows). In contrast, no apparent effects on tumor cell morphology were observed. PEDF differentiation effect on macrophages was direct as demonstrated by the significant increase in body size and dendrite length (Fig 2B and 2C) concomitant to a M1 polarization profile macrophages [34] in macrophage mono-culture. In the co-culture, PEDF also stimulated the engulfment of PC3 and CL1 cell lines by the macrophages by a factor of 4 and 8 times, respectively (Fig 2A; thick arrows). The spectral analysis of the red fluorescence present in the macrophages endocytosis vesicles was identical to the one found in the cytoplasm of tumor cells confirming that tumor cells debris are internalized by macrophages (Fig 2D). In contrast, no fluorescence was detected within the cytoplasm of RAW 264.7 mono-culture and in the extra-cellular space of co- and mono-cultures. To validate phagocytosis, we used LAMP-1 (Lysosomal Associated Membrane proteins are required for fusion of lysosomes with phagosome, later phagosomal stages and phagosomes after phagosomal fusion [43, 44]) as a specific marker of the late stage of phagocytosis. In this experiment, we demonstrated that tumor cell debris (Red) co-localized with LAMP1 (Blue) within the macrophage vesicles corroborating their phagosome-related identity (Fig 2E). Similar to RAW 264.7 cells, we found that PEDF increased by 5 fold the phagocytosis of CL1 cells by human THP-1 macrophages (Fig 3).

**PEDF stimulatory effect on tumor cells phagocytosis is apoptosis-dependent and concomitant to the production of superoxide by macrophages**

To identify the underlying mechanisms resulting in PCa cell phagocytosis under PEDF treatment, we used the caspase broad inhibitor ZVAD-FMK. Our data clearly demonstrated that
while ZVAD-FMK alone had no effect on phagocytosis, it abolished PEDF-induced phagocytosis (Fig 4A) implying an apoptosis-dependent mechanism. To investigate a possible direct tumoricidal effect of PEDF on tumor cells, we analyzed the cell cycle distribution of CL1 cells treated with or without PEDF. Interestingly, cell death remained unchanged by PEDF suggesting a macrophages-driven action (Fig 4B; Left panel). Accordingly, no apoptosis was detected in CL1 cells treated with PEDF or control (Fig 4B; Right panel). In contrast, the G1 population increased in response to PEDF corroborating PEDF effect on PCa cells differentiation as we previously demonstrated in [45]. We then treated CL1 cells with media conditioned (CM) by RAW 264.7 cells exposed to PEDF or buffer control. While % apoptosis was low in untreated CL1, % apoptosis was found significantly elevated in CM-PEDF (Fig 4C). In the meantime, PEDF treatment increased the amount of superoxide
produced by the macrophages suggesting that superoxide production could cause tumor cell apoptosis (Fig 4D; S4 Fig). In contrast, no significant increase in ROS production by

Fig 3. Validation of PEDF stimulatory effect on the phagocytosis of PCa cells using human THP-1—CL1 co-culture. (A) Representative fluorescent and Nomarski pictures of THP-1 macrophages grown as mono- or co-culture with CL1-Ctl PCa cells (Red) ± PEDF (10 nM). Nomarski and confocal images were obtained using the Nikon T1-E microscope with A1 confocal and STORM super-resolution with a 60x objective (N.A. 1.4; oil). After imaging, Regions of Interest (ROIs) were selected, and the intensity surface plot function (NIS-Elements AR 4.00.03) was used to measure the signal intensity of each ROI. ROI mean intensity was calculated from >30 representative ROI. (B) Quantification of tumor cell phagocytosis (ROI mean intensity) averaged from three different experiments. Data were represented using a boxplot graph showing the median, inter-quartile range, upper and lower quartiles, and whiskers. Statistical analysis was performed using the Student's t test. *: P<0.05.

https://doi.org/10.1371/journal.pone.0174968.g003

Fig 4. PEDF induces the phagocytosis of tumor cells through an apoptosis-dependent mechanism and possibly via the production of Superoxide radicals. (A, Left) Representative images of CL1-Ctl PCa cells (Red) and RAW 264.7 macrophages treated with buffer control, PEDF (10 nM), ZVAD (40 μM), or combination. (A, Right) Quantification of tumor cell phagocytosis (ROI mean intensity) averaged from two different experiments. Data were represented using a boxplot graph showing the median, inter-quartile range, upper and lower quartiles, and whiskers. Statistical analysis was performed using the Student’s t test. *: P<0.05. (B, Left) Cell cycle distribution of CL1 cells exposed to PEDF (10 nM). Data points represent mean ± SD of triplicate samples from two independent experiments. Error bars denote ± SD (*p < 0.05). (B, Right) Representative images of fragmented DNA (Green) in CL1 cells treated with PEDF (10 nM) or control showing that PEDF has no direct tumoricidal effect on tumor cells. Nuclei were visualized by DAPI (blue) staining. (C, Left) Representative images of fragmented DNA (Green) in CL1 cells treated with RAW 264.7 CM or CM-PEDF. Nuclei were visualized by DAPI (blue) staining. (C, Right) Apoptosis quantification measured by counting the number of apoptotic cells (Green) over the total amount of cells (>100 cells). Data points represent mean ± SD of quadruplicate samples from two independent experiments; *: p < 0.05. (D) Quantification of Superoxide production by RAW 264.7 macrophages treated with PEDF (10 nM). Data points represent mean ± SD of quadruplicate samples from two independent experiments; *: p < 0.05.

https://doi.org/10.1371/journal.pone.0174968.g004
macrophages could be found (data not shown). Our data demonstrate therefore that PEDF induces the migration of macrophages towards tumors and that, by acting on macrophages; PEDF stimulates their polarization into M1 macrophages resulting subsequently into superoxide production, tumor cell apoptosis and phagocytosis.

P18 mimics PEDF inflammatory effect in vitro

The P18 peptide (residues 39–57 of the whole PEDF) has been identified as PEDF anti-angiogenic and anti-tumoral functional epitope [33, 38]. To determine if this epitope could be involved in PEDF inflammatory role, P18 activity was tested in vitro. As PEDF, P18 stimulated significantly the migration of macrophages towards tumor spheroids (Fig 5A and 5B). P18 also modified the cell morphology of macrophages (Fig 5C). Phenotypic results were corroborated by increased iNOS and TNFa, and decreased IL10 in both RAW 264.7 macrophages and BMDMs treated with PEDF or P18 (Fig 5D). In agreement with a M1 polarization, P18 was also able to induce the phagocytosis of PCa cells in vitro (Fig 5E).
PEDF induces the expression of ATP5B and PNPLA2 in macrophages

To characterize the molecular effectors involved in PEDF inflammatory effect, we measured the expression levels of three of the known PEDF receptors (ATP5B, PNPLA2, LRP6) in macrophages. ATP5B and PNPLA2 were found expressed in a greater extent than LRP6 in RAW 264.7 cells and BMDMs collected from tumor-free and tumor-bearing mice, quantified by qRT-PCR and normalized to S15 mRNA. Data points represent mean ± SD of triplicate samples from two independent experiments. Error bars denote ± SD (*p < 0.05). ATP5B and PNPLA2 protein levels averaged from three different experiments. Error bars show standard error of the mean. *: P <0.05. (C) Western blot showing the expression levels of ATP5B and PNPLA2 in RAW 264.7 cells treated with PEDF (10 nM), P18 (10 nM) or control. Actin is used as a loading control. (D) Quantification of ATP5B and PNPLA2 protein levels averaged from three different experiments. Error bars show standard error of the mean. *: P <0.05. (E) ATP5B (Red) and PNPLA2 (Green) immunostaining of RAW 264.7 macrophages and BMDMs collected from tumor-bearing mice. Macrophages were treated with PEDF (10 nM), P18 (10 nM) or buffer control. Nuclei are visualized by DAPI (Blue) staining.

PEDF induces the expression of ATP5B and PNPLA2 in macrophages

To characterize the molecular effectors involved in PEDF inflammatory effect, we measured the expression levels of three of the known PEDF receptors (ATP5B, PNPLA2, LRP6) in macrophages. ATP5B and PNPLA2 were found expressed in a greater extent than LRP6 in RAW 264.7 cells and BMDMs (Fig 6A). Although PEDF significantly stimulated the expression of all three receptors in RAW 264.7 cells, only ATP5B and PNPLA2 were up-regulated in BMDMs by PEDF (Fig 6B). Furthermore, this increase was only found in BMDMs collected from tumor-bearing mice, but not from tumor-free mice [46] emphasizing the need of tumor sensitization/activation as seen in tumor angiogenesis [31]. Interestingly, BMMs collected from tumor-bearing mice demonstrated a M1 phenotype after PEDF treatment suggesting again a link between differentiation, and PEDF and PEDF receptors expression levels. In agreement with the qPCR results, PEDF stimulates by 2.7 and 2 fold ATP5B and PNPLA2 protein levels, respectively (Fig 6C and 6D). As well, immunofluorescence studies demonstrated elevated ATP5B and PNPLA2 in RAW 264.7 and BMDMs exposed to PEDF suggesting the involvement of both ATP5B and PNPLA2 in PEDF modulating properties on macrophages (Fig 6E).
Both receptors were also induced by P18 peptide therefore confirming that P18 mimics the modulatory action of PEDF on inflammation (Fig 6C, 6D and 6E).

**PEDF represses CD47 expression in PCa cells**

Tumor immune evasion through phagocytosis inhibition is required for tumor progression [47]. Cell surface expression of CD47 (also known as integrin-associated protein) is a common mechanism by which cells protect themselves from phagocytosis [41, 48]. CD47 is a widely expressed trans-membrane protein, and has been showed to be markedly increased in solid tumors including PCa when compared with their normal counterparts [41, 48]. CD47 have been involved in multiple cellular functions including apoptosis, proliferation, adhesion and migration with both beneficial and detrimental effects depending on the cell types and the binding partners involved [41]. Another function is to serve as a ligand for the signal regulatory protein-α (SIRPα), a protein expressed on macrophages and dendritic cells [49]. Upon binding to CD47, SIRPα initiates a “don’t eat me” signaling cascade that results in the inhibition of phagocytosis [50]. To determine if CD47 could be involved in PEDF-stimulated phagocytosis, we measured CD47 expression in PC3 and CL1 tumor cells expressing PEDF or control plasmid. In both cell lines tested, PEDF expression was concomitant to a 30–40%
inhibition in CD47 mRNA (Fig 7A). Accordingly, CD47 localization at the plasma membrane was significantly decreased by PEDF (Fig 7B, 7C and 7D) validating CD47 as a target of PEDF. In co-cultures, although CD47 remained unchanged under PEDF treatment, CD47 expression was reduced over time by PEDF suggesting that in PCa-macrophages co-cultures in which CD47 mRNA expression is increased, PEDF may need more time to repress CD47 mRNA or that macrophages could produce secreted or surface factor(s) inhibiting PEDF effect on CD47 (Fig 7E). Accordingly, SIRPα expression was repressed by PEDF emphasizing that PEDF could disturb CD47-SIRPα interaction causing phagocytosis (Fig 7E).

Role of CD47, ATP5B and PNPLA2 in PEDF’s inflammatory effect

Our findings suggest that PEDF and the P18 peptide modulate the molecular interactions between PCa cells and macrophages through bidirectional signaling. While a cis signal would

https://doi.org/10.1371/journal.pone.0174968.g008

inhibition in CD47 mRNA (Fig 7A). Accordingly, CD47 localization at the plasma membrane was significantly decreased by PEDF (Fig 7B, 7C and 7D) validating CD47 as a target of PEDF. In co-cultures, although CD47 remained unchanged under PEDF treatment, CD47 expression was reduced over time by PEDF suggesting that in PCa-macrophages co-cultures in which CD47 mRNA expression is increased, PEDF may need more time to repress CD47 mRNA or that macrophages could produce secreted or surface factor(s) inhibiting PEDF effect on CD47 (Fig 7E). Accordingly, SIRPα expression was repressed by PEDF emphasizing that PEDF could disturb CD47-SIRPα interaction causing phagocytosis (Fig 7E).

Role of CD47, ATP5B and PNPLA2 in PEDF’s inflammatory effect

Our findings suggest that PEDF and the P18 peptide modulate the molecular interactions between PCa cells and macrophages through bidirectional signaling. While a cis signal would

https://doi.org/10.1371/journal.pone.0174968.g008
result in the down-regulation of CD47 in PCa cells leading to tumor cell phagocytosis, a trans signal could be initiated on the macrophage cell surface leading subsequently to PNPLA2 and ATP5B elevation, and induction of macrophage differentiation and phagocytic activity, respectively. To test this hypothesis, we used CD47 blocking antibody to induce phagocytosis [51, 52]. In parallel, we used (S)-BEL to inhibit the calcium-independent PNPLA2, and Angiostatin as a binding competitor of PEDF on ATP5B [53, 54]. After treatment, we then quantified macrophages differentiation and phagocytic activity. Similar to PEDF and P18, CD47 blocking antibody stimulated phagocytosis (Fig 8A, S5 Fig). While PEDF and P18 induced the differentiation and phagocytic activity in macrophages, (S)-BEL co-treatment decreased significantly macrophages differentiation while phagocytosis remained unchanged (Fig 8A and 8B). Because S-BEL has been described as an inhibitor for both PNPLA2 (iPLA2\textsubscript{z}, [55]) and PNPLA9 (iPLA2\textsubscript{β}), we reproduced the experiment using Atglistatin, the first selective inhibitor for PNPLA2. As expected, our data showed that both S-BEL and Atglistatin treatments inhibited macrophage differentiation without affecting phagocytosis therefore validating PNPLA2 role in tumor cell differentiation (Fig 9). Inversely, angiostatin completely inhibited PEDF phagocytic activity. Angiostatin inhibitory effect was not due to other of its known receptors (Annexin 2, c-Met, integrin \(\alpha_\text{v}\beta_3\), S6 Fig). Surprisingly, Angiostatin treatment also resulted in a slight decrease in dendrite-length, an effect we think could be explained by Angiostatin disrupting effect on monocyte/macrophage actin cytoskeleton [56]. While the combination of PNPLA2 inhibitors and Angiostatin was toxic and did not allow us to analyze their combined effects on macrophage differentiation and phagocytosis, we investigated the relative role of CD47 and ATP5B in tumor cell phagocytosis. For this purpose, the CD47-blocking antibody was tested with angiostatin. Our data showed that angiostatin partially reversed phagocytosis-
induced by CD47 blocking (Fig 10) suggesting that both CD47 and ATP5B may participate into phagocytosis.

**Discussion**

Compelling evidence indicated that TAMs are playing a crucial role in cancer from the initiation step to tumor growth and metastasis. However, current published data using TAMs quantification in PCa remain contradictory [28, 29, 57–59] suggesting that the molecular interactions between TAMs and other cell populations from the tumor microenvironment need to be also investigated to establish better predictive tools. While PEDF’s role in inflammation-related diseases have been widely described [60, 61], our study represents the first demonstration that PEDF can modulate the interactions between PCa cells and macrophages at a molecular level. In our model, we propose that PEDF may act through a bidirectional signaling to induce apoptosis and phagocytosis of prostate tumor cells. While the *cis signal*, located in tumor cells, would lead to the repression of CD47 by PEDF and initiation of tumor cell phagocytosis, the *trans signal* would participate in the polarization and, tumoricidal and phagocytic activities of macrophages through the PNPLA2 and ATP5B initiated pathways, respectively. PNPLA2 (ATGL) was the first putative receptor identified for PEDF [55]. While highly expressed in adipose tissue, ATGL is also expressed in less extent in cardiac and skeletal muscles as well as in testis tissue [62]. Furthermore, ATGL is expressed in macrophages and, in agreement with our data, ATGL-/- macrophages showed a defect in cell polarization and migration [63]. Accordingly, treatment with S-BEL and Atglistatin reversed PEDF-induced macrophages differentiation but maintained tumor cell phagocytosis. Concomitantly, we have shown that S-BEL inhibits PNPLA2 protein expression but not ATP5B (data not shown) again suggesting a link between PEDF-induced PNPLA2 up-regulation and macrophages differentiation. In contrast, the membrane protein F1 ATP synthase is localized on endothelial cells and tumor cells [64] and has been linked to the anti-angiogenic functions of PEDF [54, 65]. The involvement of CD47 represents an important finding as blocking CD47-SIRPα interaction is currently being investigated as a therapeutic target in clinical trials [51, 66, 67]. Also, while the prognostic significance of CD47 in PCa is unknown, our data suggest that CD47 may be a good target for this type of cancer. The relative role of CD47 down-regulation and ATP5B up-regulation in phagocytosis is currently under investigation. Our preliminary data suggest that both CD47 and ATP5B may be involved (Fig 10). One could imagine that while CD47 repression triggers phagocytosis, ATP5B may play an instrumental role in the acidification of the phagocytic vesicles. Accordingly, we demonstrated that blocking PEDF binding to ATP5B using Angiostatin [54] significantly reduced phagocytosis. While we are aware that angiostatin binds to other cell surface receptors (Annexin 2, c-Met and integrin α<sub>v</sub>β<sub>3</sub>), we do not believe these receptors to be involved based on our findings summarized in S6 Fig. While Annexin 2 mRNA is slightly repressed (18%) by PEDF, Annexin 2 expression has been conversely associated with increased phagocytosis [68]. Although c-Met mRNA levels varied with PEDF and angiostatin treatment, the c-Met signaling has been shown not to have an effect on modulating cytokine expression, phagocytosis, or antigen presentation but instead promotes proliferation of macrophages [69]. As well, while the integrin α<sub>v</sub>β<sub>3</sub> has been described as necessary for phagocytosis, their inhibition under PEDF treatment is contradictory with a possible function in PEDF-induced phagocytosis [70]. To go one step further in our study, we are now proposing to optimize the CRISPR-Cas9 genome editing technology to knock-out CD47, PNPLA2 and ATP5B in tumor and macrophage cells.

Seeking new therapeutic strategies, our findings on the P18 synthetic peptide is of high interest. This peptide has been previously described by the group of Dr. Volpert as carrying
the functional epitope for PEDF anti-angiogenic and anti-tumor activities [38]. In the present study, we validated the same epitope as responsible for PEDF inflammatory function reemphasizing the great potential of this peptide as novel therapeutic target for PCa. Combination with immunotherapies that boost the activity of immune cells other than macrophages may also be interesting to test. One method could be to block the so-called checkpoint molecules—cytotoxic T lymphocyte–associated antigen 4 and programmed death 1—that inhibit T cells of the immune system [71]. As well, our results showing that PEDF can reprogram BMDCs (tumor-bearing mice) into M1 macrophages are very important as M1 reprogramming is currently recognized as the macrophages targeting therapy with the most promise [46].

While our model has been established in vitro, in vivo validation is now required with a special emphasis on the P18 peptide or P18-derived peptides as novel therapeutic agents. Still several unanswered questions/obscure points remain. 1) The precise signaling involved in macrophages polarization and tumor cell phagocytosis is uncharacterized and we are currently actively investigating these pathways. 2) The molecular mechanisms involved in tumor cell apoptosis are only partially identified. While we have demonstrated that PEDF induced the production of superoxide by macrophages concomitantly to CM-PEDF from macrophages stimulating tumor cell apoptosis, other secreted factors may be involved. Identifying these factors could explain the delay in PEDF-stimulated CD47 mRNA down-regulation (Fig 7E). As well, cell-cell contact may be involved and should be further investigated. 3) While we believe CD47 down-regulation by PEDF to be the key initiator of tumor cell phagocytosis, the participation of SIRPα is not totally proven. SIRPα inhibition by PEDF would support its involvement. On the other hand, the capacity in dissociating the interaction between CD47 and SIRPα has been described as more important than SIRPα expression level to regulate phagocytosis [41, 48]. The participation of other ligand such as SIRPγ, even though its affinity for CD47 is 10 times lower than SIRPα [72], is another possibility. Other previously identified ligand for CD47 such as thrombospondin-1 (TSP1) may also participate. As well, different “don’t eat me” signal such as calreticulin (CRP)-LRP1 (LDL receptor-related protein-1/CD91/α2-macroglobulin receptor) could be involved.

Macrophage phagocytosis of apoptotic cells, or unopsonized viable CD47(-/-) red blood cells, has been attributed to the interaction between CRP on the target cell and LRP1 on the macrophage [73]. TSP1 interaction with CRT enhances the binding of CRT to LRP1 to stimulate focal adhesion disassembly leading subsequently to an intermediate adhesive phenotype necessary for cell growth, differentiation, migration, or survival [74]. Accordingly, TSP1 connects the separate cell-surface CRT, LRP1 and CD47 receptors functionally to regulate T-Lymphocyte cell adhesion [75]. On the other hand, TCR and CD28-mediated modulatory action on TSP-1 and LRP1 have been demonstrated to participate in antigen-induced reduction in T-cell motility, enhancement of contacts with antigen-presenting cells and activation; defined pre-requisites for the stimulation of an optimal adaptive immune response [76]. Further investigations are therefore needed to determine if PEDF and its effectors could be also involved in cell-mediated immunity.

Conclusion

Our data introduce the novel concept that by targeting the tumor cell and macrophage molecular interactions, PEDF could enhance the tumoricidal activity of macrophages therefore extending the therapeutic role of PEDF in PCa.

Supporting information

S1 Fig. Protocol scheme for phagocytosis quantification. RAW 264.7 macrophages were cultured with CL1-Ctrl cells (Red) with or without PEDF (10 nM). Cells were imaged using Nomarski and Confocal microscopy (Left panels). Regions of interest (ROIs) were selected
(Inset), and the intensity surface plot function (NIS-Elements AR 4.00.03) was used to measure the signal intensity (Right panels) of each ROI. ROI mean intensity from >30 selected ROIs was then calculated and data were showed using a boxplot graph from the IBM SPSS Statistics 23 software (as represented in Figs 2A, 3B, 8A, 9A and 10).

(TIF)

**S2 Fig. Spectral imaging microscopy of fluorescence in RAW 264.7 macrophages and CL1 tumor cell co-cultures.** RAW 264.7 macrophages and CL1-Ctrl tumor cells (Fluorescent) co-cultures were imaged using the 545 nm narrow bandpass excitation filter and the 570 nm long bandpass dichroic mirror. A halogen lamp was used to obtain zero order spectra (A). Cells were imaged using a 60x oil objective (N.A 1.4) and a 500 msec exposure. Image B was obtained using a 200 μm slit width on the spectrograph. For image C, the slit width was successfully closed to 100 μm. Vertical dashed lines: representation of the final slit width as showed on image D. For image D, the slit width was closed to 0.5 μm. This ensured the highest spatial resolution from a discrete area. The areas corresponding to the CL-1 cytoplasm, phagosome in macrophages (RAW 264.7) and background (inter-cellular space) were obtained from regions of interest (ROI) as indicated by the arrows. ~100 regions in each CL1-Ctrl and RAW 264.7 cells were analyzed per experiment. The spectral outputs of the fluorescence in a macrophage phagosome and a neighboring cancer cell were concomitantly analyzed. Additionally, ROIs selected in the inter-cellular space in co-culture and RAW 264.7 mono-culture were used to set up baseline. The fluorescence data was converted to ASCII format, prior to analysis with SigmaPlot (version 8.0). Two experiments with similar results obtained were performed.

(TIF)

**S3 Fig. PEDF expression stimulates the migration of RAW 264.7 cells towards 2D conventional prostate tumor cell mono-culture in vitro.** RAW 264.7 macrophage chemotaxis to PC3-Ctrl, PC3-PEDF, CL1-Ctrl, and CL1-PEDF cells was tested using the Inverted Boyden chamber assay as we previously described in [33]. The data were normalized as the percentage of maximal migration [PC3-Ctrl- and CL1-Ctrl-induced migration taken for 100%]. PEDF specificity on macrophages migration was validated by neutralization assays using PEDF-specific blocking (MAB1059, 5μg/ml) or isotype antibodies. The migration was counted in 10 high-powered fields per condition, each condition tested in quadruplicate and the experiments done at least thrice. *: p < 0.05 is shown to illustrate statistical significance.

(TIF)

**S4 Fig. Production of Superoxide Radicals in RAW 264.7 cells using the WST-1 Tetrazolium-based in vitro assay.** RAW 264.7 macrophages were treated for 48 hours ± PEDF (10 nM). Formazan production to quantitatively estimate the Superoxide radical production was then measured using the WST-1 kit (Sigma-Aldrich). Data points represent mean ± SD of quadruplicate samples from two independent experiments. Statistical analyses were performed using the Student’s t test, *: p < 0.05.

(TIF)

**S5 Fig. Phagocytosis visualization in PCa/RAW 264.7 co-cultures treated with PNPLA2 and ATP5B inhibitors.** Representative Nomarski/Confocal images (Left panels) of PCa cell phagocytosis in CL1-Ctrl (Red)/RAW 264.7 co-cultures treated with α-CD47 (100ng/μl; Green), PEDF or P18 (10 nM) alone or PEDF/P18 in combination with either S-BEL (5μM) or Angiostatin (10 nM). Inset: representative ROI selected for quantification using the intensity surface plot function (NIS-Elements AR 4.00.03).

(TIF)
S6 Fig. mRNAs expression levels of Angiostatin receptors in RAW 264.7 cells. Total RNAs from RAW 264.7 cells treated with PEDF (10 nM), Angiostatin (10 nM), or combination were analyzed by qRT-PCR for Angiostatin receptors (Annexin A2 # 330001 PPM34399F, c-Met # 330001 PPM03726A, Integrin beta 3 # 330001 PPM03687E, and Integrin alpha V # 330001 PPM03662D; all from Qiagen) and normalized to S15. Results are presented as relative fold change compared to control non-treated cells. Data points represent mean ± SD of triplicate samples from two independent experiments.

(TIF)

Acknowledgments
Data were generated in the Image Analysis Core Facility supported by TTUHSC.

Author Contributions
Conceptualization: DMM CJ SF TN.
Data curation: DMM CJ SF.
Formal analysis: SF DMM CJ TN.
Funding acquisition: SF TN.
Investigation: DMM CJ SF.
Methodology: DMM CJ SF.
Project administration: SF TN.
Resources: SF OVV WdR.
Supervision: SF TN.
Validation: DMM CJ SF TN.
Visualization: DMM CJ SF TN.
Writing – original draft: SF.
Writing – review & editing: SF CJ TN.

References
1. Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014; 6(3):1670–90. PubMed Central PMCID: PMC4190561. https://doi.org/10.3390/cancers6031670 PMID: 25125485
2. Hu H, Hang JJ, Han T, Zhuo M, Jiao F, Wang LW. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016.
3. Jung KY, Cho SW, Kim YA, Kim D, Oh BC, Park do J, et al. Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates. Journal of pathology and translational medicine. 2015; 49(4):318–24. PubMed Central PMCID: PMC4508569. https://doi.org/10.4132/jptm.2015.06.01 PMID: 26081823
4. Kubler K, Ayub TH, Weber SK, Zivanovic O, Abramian A, Keyver-Paik MD, et al. Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecologic oncology. 2014; 135(2):176–83. https://doi.org/10.1016/j.ygyno.2014.08.028 PMID: 25173585
5. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PloS one. 2012; 7(12):e50946.
6. Jinushi M, Komohara Y. Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside. Biochimica et biophysica acta. 2015.

7. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41(1):49–61. PubMed Central PMCID: PMC4137410. https://doi.org/10.1016/j.immuni.2014.06.010 PMID: 25035953

8. Ostuni R, Kratochwill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends in immunology. 2015; 36(4):229–39. https://doi.org/10.1016/j.it.2015.02.004 PMID: 25770924

9. Guruvayoorappan C. Tumor versus tumor-associated macrophages: how hot is the link? Integrative cancer therapies. 2008; 7(2):90–5. https://doi.org/10.1177/1534735408319060 PMID: 18550889

10. Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. International journal of cancer. 2005; 117(5):701–8. https://doi.org/10.1002/ijc.21422 PMID: 16106399

11. Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L, et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. The American journal of pathology. 2003; 163(4):1233–43. PubMed Central PMCID: PMC1868302. https://doi.org/10.1016/S0002-9440(10)63483-9 PMID: 14507633

12. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer cell. 2008; 13(3):206–20. PubMed Central PMCID: PMC2643426. https://doi.org/10.1016/j.ccr.2008.01.034 PMID: 18328425

13. Lin L, Chen YS, Yao YD, Chen QJ, Chen JN, Huang SY, et al. CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer. Oncotarget. 2015; 6(33):34758–73. https://doi.org/10.18632/oncotarget.5325 PMID: 26416449

14. Fang W, Ye L, Shen L, Cai J, Huang F, Wei Q, et al. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis. 2014; 35(8):1780–7. https://doi.org/10.1093/carcin/bgu060 PMID: 24608042

15. Mitchem JB, Brennan DJ, Knohlof BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer research. 2013; 73(3):1128–41. PubMed Central PMCID: PMC3563931. https://doi.org/10.1158/0008-5472.CAN-12-2731 PMID: 23221383

16. Xuan QJ, Wang JX, Nanding A, Wang ZP, Liu H, Lian X, et al. Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients. Pathology oncology research: POR. 2014; 20(3):619–24. https://doi.org/10.1007/s12253-013-9740-z PMID: 24414992

17. Lima L, Oliveira D, Tavares A, Amar A, Cruz R, Oliveira MJ, et al. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure. Urologic oncology. 2014; 32(4):449–57. https://doi.org/10.1016/j.urolonc.2013.10.012 PMID: 24252833

18. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer cell. 2013; 23(3):277–86. https://doi.org/10.1016/j.ccr.2013.02.013 PMID: 23518347

19. Jinushi M. Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses. Cancer metastasis reviews. 2014; 33(2–3):737–45. https://doi.org/10.1007/s1055-014-9501-9 PMID: 24756203

20. Dijkstra EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer research. 2013; 73(8):2480–92. https://doi.org/10.1158/0008-5472.CAN-12-3542 PMID: 23436796
24. Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC cancer. 2010; 10:112. https://doi.org/10.1186/1471-2407-10-112 PMID: 20338029
25. Zhang H, Wang X, Shen Z, Xu J, Qin J, Sun Y. Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015; 16(4):740–50.
26. Xu L, Zhu Y, Chen L, An H, Zhang W, Wang G, et al. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Annals of surgical oncology. 2014; 21(9):3142–50. https://doi.org/10.1245/s10434-014-3601-1 PMID: 24651758
27. Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, et al. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. Journal of ovarian research. 2015; 7:19. PubMed Central PMCID: PMC3939626. https://doi.org/10.1186/1757-2215-7-19 PMID: 24507759
28. Lisbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. International journal of oncology. 2000; 17(3):445–51. PMID: 10938382
29. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer research. 2000; 60(20):5857–61. PMID: 11059783
30. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res. 2007; 22 Suppl 2:V74–80.
31. Crawford SE, Fitchev P, Veliceasa D, Volpert OV. The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder? Expert Opin Drug Discov. 2013; 8(7):769–92. https://doi.org/10.1517/17460441.2013.794781 PMID: 23642051
32. Dol JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramsson LP, et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nature medicine. 2003; 9(6):774–80. https://doi.org/10.1038/nm870 PMID: 12740569
33. Fillieur S, Volz K, Nielus T, Mirochnik Y, Huang H, Zaichuk TA, et al. Two functional epitopes of pigment epithelium-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer research. 2005; 65(12):5144–52. https://doi.org/10.1158/0008-5472.CAN-04-3744 PMID: 15958558
34. Nielus T, Samathanam C, Martinez-Marin D, Gaines N, Stevens J, Hickson J, et al. Positive correlation between PEDF expression levels and macrophage density in the human prostate. The Prostate. 2013; 73(5):549–61. https://doi.org/10.1002/pros.22595 PMID: 23038613
35. Halin S, Rudolfsson SH, Doll JA, Crawford SE, Wikstrom P, Bergh A. Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment. Neoplasia (New York, NY. 2010; 12(4):336–45.
36. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer journal (Sudbury, Mass. 2000; 6(4):220–33.
37. Nielus T, Martinez-Marin D, Hirsch J, Miller B, Rinald K, Lopez J, et al. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotheraphy in castration-refractory prostate cancer. Cell death & disease. 2014; 5:e1210.
38. Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A, Shifrin V, Beckmann R, et al. Short pigment epithelium-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res. 2009; 15(5):1655–63. https://doi.org/10.1158/1078-0432.CCR-08-2113 PMID: 19223494
39. Gul N, Babes L, Siegmond K, Korthouver R, Bogels M, Braster R, et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. The Journal of clinical investigation. 2014; 124(2):812–23. PubMed Central PMCID: PMC3904600. https://doi.org/10.1172/JCI86776 PMID: 24430180
40. Weischenfeldt J, Porse B. Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. CSH protocols. 2008; 2008:pdb prot5080.
41. Murata Y, Kotani T, Ohashi H, Matozaki T. The CD47-SIRPalpha signalling system: its physiological roles and therapeutic application. Journal of biochemistry. 2014; 155(6):335–44. https://doi.org/10.1093/jb/mvu017 PMID: 24627525
42. Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer JP, Ho PY, McKenna KM, et al. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proceedings of the National
43. Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 2007; 26(2):313–24. PubMed Central PMCID: PMC2543450. https://doi.org/10.1038/sj.emboj.7601511 PMID: 17245426

44. Wagner BJ, Lindau D, Ripper D, Stierhof YD, Glätzel J, Witte M, et al. Phagocytosis of dying tumor cells by human peritoneal mesothelial cells. Journal of cell science. 2011; 124(10):1644–54. https://doi.org/10.1242/jcs.078907 PMID: 21525033

45. Nelius TM-M; Hirsch J.; Miller B.; Rinard K.; Lopez J.; De Riese W.; Filleur S. Pigment Epithelium-Derived Factor Expression Prolongs Survival and Enhances the Cytotoxicity of Low-dose Chemotherapy in Castration-Refractory Prostate Cancer. Cell Death & Disease. 2014;Accepted for publication.

46. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends in immunology. 2012; 33(3):119–26. https://doi.org/10.1016/j.it.2011.12.001 PMID: 22277903

47. Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends in immunology. 2010; 31(6):212–9. PubMed Central PMCID: PMCPMC3646798. https://doi.org/10.1016/j.it.2010.04.001 PMID: 20452821

51. Lindberg FP, Lublin DM, Telen MJ, Veile RA, Miller YE, Donis-Keller H, et al. Rh-related antigen CD47 is the signal-transducer integrin-associated protein. The Journal of biological chemistry. 1994; 269(3):1567–70. PMID: 8294396

52. Lindberg FP, Lublin DM, Telen MJ, Veile RA, Miller YE, Donis-Keller H, et al. Rh-related antigen CD47 is the signal-transducer integrin-associated protein. The Journal of biological chemistry. 1994; 269(3):1567–70. PMID: 8294396

53. Moran JM, Buller RM, McHowat J, Turk J, Wohltmann M, Gross RW, et al. Genetic and pharmacologic evidence that calcium-independent phospholipase A2beta regulates virus-induced inducible nitric-oxide synthase expression by macrophages. The Journal of biological chemistry. 2005; 280(30):28162–8. https://doi.org/10.1074/jbc.M500353200 PMID: 15946940

54. Notari L, Arakaki N, Mueller D, Meier S, Amaral J, Becerra SP. Pigment epithelium-derived factor binds to cell-surface F(1)-ATP synthase. The FEBS journal. 2010; 277(9):2192–205. https://doi.org/10.1111/j.1742-4658.2010.07641.x PMID: 20412062

55. Notari L, Baladron V, Aroca-Aguilar JD, Ballo N, Heredia R, Meyer C, et al. Identification of a lipase-linked cell-membrane receptor for pigment epithelium-derived factor (PEDF). The Journal of biological chemistry. 2006; 281(49):38022–37. https://doi.org/10.1074/jbc.M600353200 PMID: 17032652

56. Perri SR, Annabi B, Galipeau J. Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton. FASEB J. 2007; 21(14):3928–36. https://doi.org/10.1096/fj.07-8158com PMID: 17622568

57. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. Journal of immunological methods. 2009; 348(1–2):9–17. https://doi.org/10.1016/j.jim.2009.06.004 PMID: 19592894

58. Gollapudi K, Galec T, Grogan T, Zhang H, Said JW, Huang J, et al. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. American journal of cancer research. 2013; 3(5):523–9. PubMed Central PMCID: PMC3816972. PMID: 24224130

59. Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M, et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU international. 2011; 107(12):1916–22. https://doi.org/10.1111/j.1464-410X.2010.08904.x PMID: 21044246

60. Filleur S, Nellis T, de Riese W, Kennedy RC. Characterization of PEDF: a multi-functional serpin family protein. Journal of cellular biochemistry. 2009; 106(5):769–75. https://doi.org/10.1002/jcb.22072 PMID: 19180572
61. Principe DR, DeCant B, Diaz AM, Mangan RJ, Hwang R, Lowy A, et al. PEDF inhibits pancreatic tumori-
genesis by attenuating the fibro-inflammatory reaction. Oncotarget. 2016; 7(19):28218–34. https://doi.org/10.18632/oncotarget.8587 PMID: 27058416

62. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, et al. Impaired Rho GTPase activation abrogates cell polarization and migration in macrophages with defective lipolysis. Cellular and molecular life sciences: CMLS. 2011; 68(23):3933–47. PubMed Central PMCID: PMC3214256. https://doi.org/10.1007/s00018-011-0686-4 PMID: 21533980

63. Aflaki E, Balenga NA, Luschnig-Schratt P, Wolinski H, Povoden S, Chandak PG, et al. Impaired Rho GTPase activation abrogates cell polarizat ion and migration in macropha ges with defective lipolysis. Cellular and molecular life sciences: CMLS. 2011; 68(23):3933–47. PubMed Central PMCID: PMC3214256. https://doi.org/10.1007/s00018-011-0686-4 PMID: 21533980

64. Das B, Mondragon MO, Sadeghian M, Hatcher VB, Norin AJ. A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines. The Journal of experimental medicine. 1994; 180(1):273–81. PubMed Central PMCID: PMC2191542. PMID: 8006588

65. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(17):6565–61. PubMed Central PMCID: PMC3440054. https://doi.org/10.1073/pnas.1121629109 PMID: 22451919

66. Stukes S, Coelho C, Rivera J, Jedlicka AE, Hajjar KA, Casadevall A. The Membrane Phospholipid Binding Protein Annexin A2 Promotes Phagocytosis and Nonlytic Exocytosis of Cryptococcus neoformans and Impacts Survival in Fungal Infection. J Immunol. 2016; 197(4):911–21. PubMed Central PMCID: PMC5160961. https://doi.org/10.4049/jimmunol.1501855 PMID: 27371272

67. Nilsson A, Vesterlund L, Oldenborg PA. Macrophage expression of LRP1, a receptor for apoptotic cells and unopsonized erythrocytes, can be regulated by glucocorticoids. Biochemical and biophysical research communications. 2012; 417(4):1304–9. https://doi.org/10.1016/j.bbrc.2011.12.137 PMID: 22234309

68. Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. Annual review of immunology. 2014; 32:25–50. https://doi.org/10.1146/annurev-immunol-032713-120142 PMID: 24215318

69. Nilsson A, Vesterlund L, Oldenborg PA. Macrophage expression of LRP1, a receptor for apoptotic cells and unopsonized erythrocytes, can be regulated by glucocorticoids. Biochemical and biophysical research communications. 2012; 417(4):1304–9. https://doi.org/10.1016/j.bbrc.2011.12.137 PMID: 22234309

70. Yan Q, Murphy-Ullrich JE, Song Y. Structural insight into the role of thrombospondin-1 binding to calreti-
culin in calreticulin-induced focal adhesion disassembly. Biochemistry. 2010; 49(17):3685–94. PubMed Central PMCID: PMC2942767. https://doi.org/10.1021/bi902067f PMID: 20337411

71. Li SS, Liu L, Zhuo C, Li X, Uzel M, Sundqvist KG. Endogenous thrombospondin-1 is a cell-surface ligand for regu-
lation of integrin-dependent T-lymphocyte adhesion. Blood. 2006; 108(9):3112–20. https://doi.org/10.1182/blood-2006-04-016832 PMID: 16835379

72. Bergstrom SE, Uzel M, Talmo T, Bergdahl E, Sundqvist KG. Antigen-induced regulation of T-cell motility, interaction with antigen-presenting cells and activation through endogenous thrombospondin-1 and its receptors. Immunology. 2015; 144(4):687–703. PubMed Central PMCID: PMC4368175. https://doi.org/10.1111/imm.12424 PMID: 25393517